advertisement
Abstract #48282 Published in IGR 13-4
Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature
Tressler CS; Wiseman RL; Dombi TM; Jessen B; Huang K; Kwok KK; Wirostko BMBritish Journal of Ophthalmology 2011; 95: 1490-1495
AIM: To determine if there is an association between the use of latanoprost ophthalmic solution and malignant melanoma and to assess the evidence of a plausible biological mechanism. METHODS: Two safety databases were reviewed: one representing all latanoprost (n=24) and fixed-combination latanoprost/timolol (n=16) clinical trials conducted from November 1992 through November 2007 and a global safety database of all spontaneous non-trial-related clinical reports spanning 13 and 9 years for latanoprost and for latanoprost/timolol, respectively. A systematic PubMed search for studies evaluating potential mechanisms was conducted. RESULTS: Amongst 12,880 latanoprost-treated subjects in clinical trials, no reported cases of ocular melanoma and three cases of cutaneous melanoma were identified. Of 19,940 cases recorded in the global safety database, 22 reports of ocular/cutaneous neoplasms were identified. Of these neoplasms, 11 were ocular and six were cutaneous melanomas. Possible association with latanoprost use could not be excluded in three ocular and one periorbital report. In vitro and in vivo data were consistent with a mechanism whereby the increased iris pigmentation results from stimulation of melanin synthesis by induction of tyrosinase transcription without increasing mitotic activity. CONCLUSION: There is no evidence at present that establishes a link between latanoprost use and either ocular or cutaneous melanoma.
Pfizer Inc., New York, NY, USA. charles.s.tressler@pfizer.com
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
